basically all the work they are doing now brings to the table( if a success) the 50% probability that the drug they are working on will be successful in human trials. Given success takes them to 2-3 billion mcap or so, there needs to be a rerate to half that ( say 750m to be cons) if there are no hiccoughs at this junction. so that's retina in a dish and phagocytosis issues with good outcomes. Latest company release suggests by end March.
Bear in mind the platform and the othre 5 drugs they are working are valued at zero currently and in all these scenarios.
I am hoping we get at least half the relevant valuation in the lead up.... so 375m. That's still another 80% from here.... I just removed my small parcel for sale at 7.1c.....
PYC Price at posting:
6.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)